Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Hong Kong, Shares Jump 6%
MT Newswires Live2025-11-27
Recce Pharmaceuticals (ASX:RCE) was granted a Family 4 patent by the Hong Kong Special Administrative Region for its anti-infectives, according to a Thursday Australian bourse filing.
The patent, expiring in 2041, relates to the process for preparation of the anti-infectives, as well as the use of its R327 and R529 therapy candidates, particularly in the treatment of bacterial infections and viral infections.
It also relates to the administration of the anti-infectives by oral, inhalation, transdermal delivery, or by injection. They can also be delivered as an aerosol, gel, topical foam, or ointment.
The firm's shares jumped 6% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
